Rhythm Pharmaceuticals, Inc.
RYTM
Clasificación en acciones
#3012
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Precio por acción
$88.37
Capitalización bursátil
$6.08B
Cambio (1 día)
2.55%
Cambio (1 año)
-19.87%
País
US
Comercio Rhythm Pharmaceuticals, Inc. (RYTM)
Categoría
Healthcare
Historial de rendimiento por dividendo de Rhythm Pharmaceuticals, Inc. (RYTM)
Rendimiento por dividendo (TTM) de Rhythm Pharmaceuticals, Inc. (símbolo bursátil: RYTM) al 2023-12-31: 0.00%
Rendimiento promedio por dividendo de los últimos 5 años: 0.02%
Rendimiento promedio por dividendo de los últimos 5 años: 0.02%
Historial de rendimiento por dividendo de Rhythm Pharmaceuticals, Inc. (RYTM) desde 2012 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
| Año | Rendimiento por dividendo | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.12% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Rendimientos por dividendo (TTM) de empresas similares o competidoras
| Empresa | Rendimiento por dividendo | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
